{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:26:54Z","timestamp":1793125614798,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during the COVID-19 pandemic includes burnout, depression, and posttraumatic stress disorder (PTSD).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate whether psilocybin therapy could improve symptoms of depression, burnout, and PTSD in US clinicians who developed these symptoms from frontline clinical work during the pandemic.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind randomized clinical trial enrolled participants from February to December 2022. Participants included physicians, APPs, and nurses who provided frontline care for more than 1 month during the pandemic and had no prepandemic mental health diagnoses but had moderate or severe symptoms of depression at enrollment. Participants were randomly assigned to either the psilocybin or niacin arm. Data analysis was conducted between December 2023 and May 2024 and was based on the intention-to-treat principle.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n One intervention episode consisted of 2 preparation visits, 1 medication session, and 3 integration visits. At the medication session, participants received psilocybin, 25 mg, or niacin, 100 mg, orally.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n \n The primary outcome was a change from baseline (preparation 1 session) to day 28 (after medication administration) in symptoms of depression as measured by the clinician-administered Montgomery-Asberg Depression Rating Scale (MADRS) used by blinded raters. The secondary outcomes were a change in symptoms of burnout (measured with the Stanford Professional Fulfillment Index [SPFI]) and symptoms of PTSD (measured with the Posttraumatic Stress Disorder Checklist for\n Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition<\/jats:italic>\n [PCL-5]).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 30 clinicians (15 females [50%]; mean [range] age, 38 [29-60] years) participated, of whom 15 were randomly assigned to receive psilocybin and 15 to receive niacin. The mean change in symptoms of depression (MADRS scores) from preparation 1 session to day 28 was \u221221.33 (7.84) in the psilocybin arm compared with \u22129.33 (7.32) in the niacin arm, with a mean difference between arms of \u221212.00 (95% CI, \u221217.67 to \u22126.33;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), a decrease in MADRS scores indicating improvement. The mean change in SPFI scores from preparation 1 session to day 28 showed a numerically larger improvement in symptoms of burnout in the psilocybin compared with the niacin arm (\u22126.40 [5.00] vs \u22122.33 [5.97];\n P<\/jats:italic>\n \u2009=\u2009.05) but was not statistically significant. Since the SPFI score change did not reach statistical significance, the PCL-5 score change was evaluated descriptively. The mean change in PCL-5 scores showed a numerically larger decrease in symptoms of PTSD from preparation 1 session to day 28 in the psilocybin vs the niacin arm (\u221216.67 [15.04] vs \u22126.73 [10.69]), but this difference was not statistically tested.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial found that psilocybin therapy resulted in a significant, sustained reduction in symptoms of depression experienced by clinicians after frontline work during the COVID-19 pandemic. The findings establish psilocybin therapy as a new paradigm of treatment for this postpandemic condition.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05163496<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.49026","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:31:54Z","timestamp":1733398314000},"page":"e2449026","source":"Crossref","is-referenced-by-count":47,"title":["Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic"],"prefix":"10.1001","volume":"7","author":[{"given":"Anthony L.","family":"Back","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timara K.","family":"Freeman-Young","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladybird","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmeet","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey K.","family":"Baker","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Myers","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie A.","family":"McGregor","sequence":"additional","affiliation":[{"name":"Orion Center for Integrative Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalin","family":"Harvey","sequence":"additional","affiliation":[{"name":"Quantified Citizen, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Kollefrath","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Sorta","sequence":"additional","affiliation":[{"name":"Psychiatric Alternatives and Wellness Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Kaelen","sequence":"additional","affiliation":[{"name":"Wavepaths Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"zoi241372r2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.952783","article-title":"Burnout status of healthcare workers in the world during the peak period of the COVID-19 pandemic.","volume":"13","author":"Ulfa","year":"2022","journal-title":"Front Psychol"},{"key":"zoi241372r3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jad.2023.03.012","article-title":"The prevalence of probable mental health disorders among hospital healthcare workers during COVID-19: a systematic review and meta-analysis.","volume":"330","author":"Lee","year":"2023","journal-title":"J Affect Disord"},{"key":"zoi241372r4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.750529","article-title":"Burnout among healthcare workers in the COVID 19 era: a review of the existing literature.","volume":"9","author":"Leo","year":"2021","journal-title":"Front Public Health"},{"issue":"21","key":"zoi241372r5","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1001\/jama.2020.5893","article-title":"Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic.","volume":"323","author":"Shanafelt","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"zoi241372r6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/wvn.12439","article-title":"Clinician mental health and well-being during global healthcare crises: evidence learned from prior epidemics for COVID-19 pandemic.","volume":"17","author":"Jun","year":"2020","journal-title":"Worldviews Evid Based Nurs"},{"issue":"2","key":"zoi241372r8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11606-021-07252-z","article-title":"The impact of the COVID-19 pandemic on mental health, occupational functioning, and professional retention among health care workers and first responders.","volume":"37","author":"Hendrickson","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"18","key":"zoi241372r9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2021.2701","article-title":"Navigating attacks against health care workers in the COVID-19 era.","volume":"325","author":"Larkin","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"zoi241372r10","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.mayocp.2022.09.002","article-title":"Changes in burnout and satisfaction with work-life integration in physicians during the first 2 years of the COVID-19 pandemic.","volume":"97","author":"Shanafelt","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"zoi241372r11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1133484","article-title":"The relationship between physician burnout and depression, anxiety, suicidality and substance abuse: a mixed methods systematic review.","volume":"11","author":"Ryan","year":"2023","journal-title":"Front Public Health"},{"key":"zoi241372r12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fpsyg.2019.00284","article-title":"The relationship between burnout, depression, and anxiety: a systematic review and meta-analysis.","volume":"10","author":"Koutsimani","year":"2019","journal-title":"Front Psychol"},{"key":"zoi241372r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"18","key":"zoi241372r14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi241372r15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"zoi241372r16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"12","key":"zoi241372r17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi241372r18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"zoi241372r19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/0022167817715966","article-title":"Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress.","volume":"57","author":"Swift","year":"2017","journal-title":"J Humanist Psychol"},{"issue":"11","key":"zoi241372r20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"zoi241372r21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-9-26","article-title":"The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in major depressive disorder.","volume":"9","author":"Fantino","year":"2009","journal-title":"BMC Psychiatry"},{"key":"zoi241372r24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","article-title":"The use of the psychological flexibility model to support psychedelic assisted therapy.","volume":"15","author":"Watts","year":"2020","journal-title":"J Contextual Behav Sci"},{"issue":"7","key":"zoi241372r25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamapsychiatry.2023.1554","article-title":"Importance of integrating spiritual, existential, religious, and theological components in psychedelic-assisted therapies.","volume":"80","author":"Palitsky","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi241372r27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy.","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"zoi241372r28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA).","volume":"192","author":"Williams","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"1","key":"zoi241372r29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40596-017-0849-3","article-title":"A brief instrument to assess both burnout and professional fulfillment in physicians: reliability and validity, including correlation with self-reported medical errors, in a sample of resident and practicing physicians.","volume":"42","author":"Trockel","year":"2018","journal-title":"Acad Psychiatry"},{"issue":"6","key":"zoi241372r30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/jts.22059","article-title":"The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): development and initial psychometric evaluation.","volume":"28","author":"Blevins","year":"2015","journal-title":"J Trauma Stress"},{"issue":"1","key":"zoi241372r31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.therap.2015.11.001","article-title":"Clinical research and methodology: what usage and what hierarchical order for secondary endpoints?","volume":"71","author":"Laporte","year":"2016","journal-title":"Therapie"},{"issue":"5","key":"zoi241372r32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1185\/030079908X291958","article-title":"The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach.","volume":"24","author":"Duru","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"zoi241372r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109504","article-title":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.","volume":"231","author":"Wulff","year":"2023","journal-title":"Neuropharmacology"},{"issue":"6","key":"zoi241372r34","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"zoi241372r35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry.","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi241372r36","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","article-title":"Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.","volume":"14","author":"Breeksema","year":"2024","journal-title":"Sci Rep"},{"issue":"7","key":"zoi241372r37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context.","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"3","key":"zoi241372r38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.","volume":"143","author":"Turkoz","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"zoi241372r39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.amjmed.2023.10.003","article-title":"Systematic review and meta-analysis of randomized trials testing interventions to reduce physician burnout.","volume":"137","author":"Haslam","year":"2024","journal-title":"Am J Med"},{"issue":"2","key":"zoi241372r40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1037\/pas0001098","article-title":"Reliable and clinically significant change in the clinician-administered PTSD Scale for DSM-5 and PTSD Checklist for DSM-5 among male veterans.","volume":"34","author":"Marx","year":"2022","journal-title":"Psychol Assess"},{"key":"zoi241372r22","doi-asserted-by":"crossref","DOI":"10.1093\/9780197762622.001.0001","volume-title":"EMBARK Psychedelic Therapy: A New Approach for the Whole Person","author":"Brennan","year":"2024"},{"key":"zoi241372r23","volume-title":"Holotropic Breathwork: A New Approach to Self-Exploration and Therapy","author":"Grof","year":"2023"},{"key":"zoi241372r1","unstructured":"Ouyang? H. I\u2019m an E.R. doctor in New York. None of us will ever be the same. The New York Times. April 14, 2020. Accessed October 24, 2024. https:\/\/www.nytimes.com\/2020\/04\/14\/magazine\/coronavirus-er-doctor-diary-new-york-city.html"},{"key":"zoi241372r7","unstructured":"Knoll? C, Watkins? A, Rothfeld? M. \u2018I couldn\u2019t do anything\u2019: the virus and an E.R. doctor\u2019s suicide. The New York Times. July 11, 2020. Accessed October 24, 2024. https:\/\/www.nytimes.com\/2020\/07\/11\/nyregion\/lorna-breen-suicide-coronavirus.html"},{"key":"zoi241372r26","unstructured":"Kaelen? M. Wavepaths home page. Accessed October 24, 2024. https:\/\/wavepaths.com\/?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2827553\/back_2024_oi_241372_1751917242.93784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:00:35Z","timestamp":1752159635000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2827553"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49026","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}